TY - JOUR
T1 - Malignant pleural mesothelioma: an update on diagnosis and treatment options
AU - Kondola, S.
AU - Manners, D.
AU - Nowak, Anna
PY - 2016/6
Y1 - 2016/6
N2 - Malignant pleural mesothelioma (MPM) represents a significant diagnostic and therapeutic challenge and is almost always a fatal disease. Imaging abnormalities are common, but have a limited role in distinguishing mesothelioma from metastatic pleural disease. Similarly, minimally invasive biomarkers have shown promise but also have limitations in the diagnosis of mesothelioma. In experienced centers, cytology and immunohistochemistry are now sufficient to diagnose the epithelioid subtype of mesothelioma, which can reduce the need for more invasive diagnostic investigations. Prognosis of MPM is modestly impacted by oncological treatments. Chemotherapy with cisplatin and pemetrexed is considered the standard of care, though the addition of bevacizumab to the platinum doublet may be the new standard of care. New targeted therapies have demonstrated some promise and are being addressed in clinical trials. This review focuses on the current data on the diagnostic and therapeutic issues of MPM.
AB - Malignant pleural mesothelioma (MPM) represents a significant diagnostic and therapeutic challenge and is almost always a fatal disease. Imaging abnormalities are common, but have a limited role in distinguishing mesothelioma from metastatic pleural disease. Similarly, minimally invasive biomarkers have shown promise but also have limitations in the diagnosis of mesothelioma. In experienced centers, cytology and immunohistochemistry are now sufficient to diagnose the epithelioid subtype of mesothelioma, which can reduce the need for more invasive diagnostic investigations. Prognosis of MPM is modestly impacted by oncological treatments. Chemotherapy with cisplatin and pemetrexed is considered the standard of care, though the addition of bevacizumab to the platinum doublet may be the new standard of care. New targeted therapies have demonstrated some promise and are being addressed in clinical trials. This review focuses on the current data on the diagnostic and therapeutic issues of MPM.
UR - http://www.scopus.com/inward/record.url?scp=84973537753&partnerID=8YFLogxK
U2 - 10.1177/1753465816628800
DO - 10.1177/1753465816628800
M3 - Review article
C2 - 26873306
VL - 10
SP - 275
EP - 288
JO - THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE
JF - THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE
SN - 1753-4658
IS - 3
ER -